Welcome to our dedicated page for Astera Labs SEC filings (Ticker: ALAB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Astera Labs's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Astera Labs's regulatory disclosures and financial reporting.
Astera Labs, Inc. (ALAB) director Stefan A. Dyckerhoff reported selling a total of 12,499 shares of common stock on September 2, 2026, in open-market transactions at weighted average prices between about $273 and $277 per share. The sales were made pursuant to a Rule 10b5-1 trading plan adopted on December 1, 2025. Portions of the shares were held directly, while others were held indirectly through a trust and a limited partnership, and certain indirect positions and irrevocable trusts are reported with the filer disclaiming beneficial ownership except for his pecuniary interest.
Astera Labs, Inc. (ALAB) director Manuel Alba reported that entities associated with him sold a total of 183,000 shares of Common Stock on September 1, 2026. The sales were executed indirectly through the Alba 2003 Living Trust and Casa Alameda 2007, LLC at weighted average prices ranging from about $276.72 to $288.99 per share.
The trades occurred automatically pursuant to a Rule 10b5-1 trading plan adopted on May 22, 2026. After these transactions, Alba also reports indirect ownership of 5,000 shares through his spouse and direct ownership of 2,351 shares, while disclaiming beneficial ownership of the trust and LLC shares except for any pecuniary interest.
Astera Labs, Inc. (ALAB) received a notice that affiliate Stefan A. Dyckerhoff intends to sell up to 12,499 shares of common stock through Stifel Nicolaus & Company on NASDAQ, with an estimated aggregate market value of $3,436,755.00 as of the planned sale date of September 2, 2026. The notice states that 171,410,000 shares of common stock were outstanding. In the past three months, Dyckerhoff reported sales of 12,499 shares on July 1, 2026 and 12,499 shares on August 6, 2026.
Astera Labs, Inc. (ALAB) is the issuer for which a Form 144 notice has been filed covering a proposed resale of restricted/controlled shares. The filing states that the Mar 2011 Childrens Trust intends to sell up to 170,000 shares of common stock of Astera Labs through Morgan Stanley Smith Barney LLC, with a reported value of $50,486,600, to be sold on NASDAQ. These shares were acquired on 03/21/2018 in a private acquisition from the issuer and were paid for in cash. The notice also lists Rule 10b5-1 plan sales during the past three months by related accounts, including sales of 170,000, 33,000, and 150,000 Astera Labs common shares on 07/01/2026.
Astera Labs, Inc. (ALAB) received a notice that Alba 2003 Living Trust intends to sell up to 150,000 shares of its common stock under Rule 144 through Morgan Stanley Smith Barney LLC Executive Financial Services. The notice lists an aggregate market value of $44,547,000.00 for these shares, compared with 173,485,104 shares of common stock outstanding.
The shares to be sold were acquired on 03/21/2018 via a private acquisition from the issuer for cash. The filing also reports recent 10b5-1 sales during the past three months by related entities, including sales of 170,000, 33,000, and 150,000 ALAB common shares.
Astera Labs, Inc. (ALAB) has a beneficial holder, Casa Alameda 2007, LLC, that submitted a notice under Rule 144 covering a potential sale of up to 33,000 shares of common stock through Morgan Stanley Smith Barney LLC, with an indicated aggregate market value of $9,800,340 and a proposed sale date of September 1, 2026 on Nasdaq.
The 33,000 shares were originally acquired on November 30, 2018 in a private acquisition from the issuer or an affiliate for cash. The notice also lists prior Rule 10b5-1 plan sales during the past three months by related trusts and entities holding Astera Labs common stock.
Astera Labs, Inc. (ALAB) reported that President and COO Gajendra Sanjay sold an aggregate 90,630 shares of Common Stock on August 17, 2026. The company states these shares were sold automatically under a pre-established “sell to cover” arrangement to satisfy tax withholding obligations arising from the vesting and settlement of previously granted restricted stock units, and that the transactions did not represent discretionary trades by the executive.
Weighted-average sale prices for the blocks ranged from about $333.60 to $352.11 per share, each over narrower intraday price ranges described in the footnotes. In addition, indirect holdings reported for estate-planning vehicles included 5,290,402 shares held by Trust 1, and 615,000 shares each held by Trust 2 and Trust 3, for which Sanjay disclaims beneficial ownership except for any pecuniary interest.
Astera Labs, Inc. (ALAB) reported that its General Counsel and Secretary, Philip Mazzara, had multiple sales of common stock on August 17, 2026. In total, 6,801 shares were sold in open-market block trades at reported per-share prices between $333.6377 and $352.1027.
According to the company’s disclosure, these shares were sold to satisfy tax withholding obligations arising from the vesting and settlement of previously granted restricted stock units. The company states the sales were automatic under a pre-established “sell to cover” election made by Astera Labs and did not represent discretionary trading by Mazzara.
Astera Labs, Inc. (ALAB) reported that Chief Executive Officer and director Jitendra Mohan executed multiple sales of the company’s Common Stock on August 17, 2026. In total, 90,630 shares were sold in a series of open-market block trades at weighted-average prices generally between the mid-$330s and mid-$350s per share. According to the disclosure, these shares were required to be sold to satisfy tax withholding obligations arising from the vesting and settlement of previously granted restricted stock units, under an advance “sell to cover” election made by Astera Labs; the filing states these were not discretionary trades by Mohan. The filing also lists significant indirect holdings in various estate-planning and living trusts, including positions such as 699,999 shares held by an estate planning trust and 3,789,232 shares held by a living trust, for which Mohan disclaims beneficial ownership except for any pecuniary interest.
Astera Labs, Inc. director Stefan A. Dyckerhoff reported sales of 12,499 shares of common stock on 2026-08-06. The shares were sold in multiple open-market transactions at weighted average prices around $309–$313 per share, pursuant to a Rule 10b5-1 trading plan adopted on December 1, 2025. Some shares were held directly, while others were held through trusts and a limited partnership for which he serves as trustee or through related roles, and he disclaims beneficial ownership beyond his pecuniary interest.